Glucosamine inhibits IL-1β-mediated IL-8 production in prostate cancer cells by MAPK attenuation

Journal of Cellular Biochemistry

Volumn 108, Issue 2, 2009, Pages 489-498

  Tsai, Cheng Yen ^a   Lee, Tzong Shyuan ^a   Kou, Yu Ru ^a   Wu, Yuh Lin ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NONE   (Taiwan)

Author keywords

Glucosamine; IL 1 ; IL 8; Prostate cancer

Indexed keywords

GLUCOSAMINE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CHRONIC INFLAMMATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSAMINE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; RNA, MESSENGER; TIME FACTORS;

EID: 70349233828     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22278     Document Type: Article

References (34)

1. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. 2006. Inflammation and cancer: How hot is the link? Biochem Pharmacol 72:1605-1621.
2. Amanatullah DF, Reutens AT, Zafonte BT, Fu M, Mani S, Pestell RG. 2000. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 5:D372-D390.
3. Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, Yulevitch A, Gurfinkel R, Werman A, White RM, Argov S, Shendler Y, Bjorkdahl O, Dohlsten M, Zoller M, Segal S, Voronov E. 2000. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates antitumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol 479:277-288.
4. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. 2007. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 67:6854-6862.
5. Brat DJ, Bellail AC, Van Meir EG. 2005. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7:122-133.
6. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39. (Pubitemid 38524696)
7. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860-867.
8. d'Abusco AS, Calamia V, Cicione C, Grigolo B, Politi L, Scandurra R. 2007. Glucosamine affects intracellular signalling through inhibition of mitogen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 9:R104.
9. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. 2007. Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269.
10. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del BD. 2008. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 107:871-882.
11. Hanada T, Yoshimura A. 2002. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 13:413-421.
12. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 6:2104-2119. (Pubitemid 30305111)
13. Kamohara H, Takahashi M, Ishiko T, Ogawa M, Baba H. 2007. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol 31:627-632.
14. Lawrence T, Gilroy DW. 2007. Chronic inflammation: A failure of resolution? Int J Exp Pathol 88:85-94.
15. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. 2004. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 23:2197-2205. (Pubitemid 38482534)
16. Mantovani A. 2005. Cancer: Inflammation by remote control. Nature 435:752-753.
17. Mantovani A. 2007. Cancer: An infernal triangle. Nature 436:547-548.
18. McCarty MF. 1994. The neglect of glucosamine as a treatment for osteoarthritis - a personal perspective. Med Hypotheses 42:323-327. (Pubitemid 24173236)
19. Mendis E, Kim MM, Rajapakse N, Kim SK. 2008. Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-kappaB and MAPK expressions. Bioorg Med Chem 16:8390-8396.
20. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63. (Pubitemid 14203433)
21. Neuder LE, Keener JM, Eckert RE, Trujillo JC, Jones SL. 2009. Role of p38 MAPK in LPS induced pro-inflammatory cytokine and chemokine gene expression in equine leukocytes. Vet Immunol Immunopathol 129:192-199.
22. O'Neill LA. 2008. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226:10-18.
23. Platz EA, De Marzo AM. 2004. Epidemiology of inflammation and prostate cancer. J Urol 171:S36-S40.
24. Rasmussen MK, Iversen L, Johansen C, Finnemann J, Olsen LS, Kragballe K, Gesser B. 2008. IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. Inflamm Res 57:329-339.
25. Shi Q, Xiong Q, Le X, Xie K. 2001. Regulation of interleukin-8 expression by tumor-associated stress factors. J Interferon Cytokine Res 21:553-566. (Pubitemid 32916084)
26. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA. 2005. Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64:40-49. (Pubitemid 40734737)
27. van der Poel HG. 2007. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 61:104-139. (Pubitemid 46073780)
28. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL, Jr., Vessella RL, Ralph D. 1999. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53:139-147. (Pubitemid 29016629)
29. Voronov E, Shouval DS, Krelin Y, Cagnano E, Benharroch D, Iwakura Y, Dinarello CA, Apte RN. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100:2645-2650. (Pubitemid 36297552)
30. Voronov E, Carmi Y, Apte RN. 2007. Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601:265-270.
31. Walsh AJ, O'neill CW, Lotz JC. 2007. Glucosamine HCl alters production of inflammatory mediators by rat intervertebral disc cells in vitro. Spine J 7:601-608.
32. Wurm S, Neumeier M, Weigert J, Wanninger J, Gerl M, Gindner A, Schaffler A, Aslanidis C, Scholmerich J, Buechler C. 2008. Insulin induces monocytic CXCL8 secretion by the mitogenic signalling pathway. Cytokine 44:185-190.
33. Xie K. 2001. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12:375-391.
34. Zachara NE, Hart GW. 2006. Cell signaling, the essential role of O-GlcNAc. Biochim Biophys Acta 1762:599-617.